Epigenomics Ag Stock Probability Of Bankruptcy
| EPGNF Stock | USD 0.50 2.00 80.00% |
Epigenomics |
Epigenomics AG Company chance of financial distress Analysis
Epigenomics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Epigenomics Probability Of Bankruptcy | Less than 36% |
Most of Epigenomics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Epigenomics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Epigenomics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Epigenomics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Epigenomics AG financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Epigenomics AG has a Probability Of Bankruptcy of 36.0%. This is 16.84% lower than that of the Healthcare sector and 11.85% lower than that of the Diagnostics & Research industry. The probability of bankruptcy for all United States stocks is 9.62% higher than that of the company.
Epigenomics Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Epigenomics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Epigenomics could also be used in its relative valuation, which is a method of valuing Epigenomics by comparing valuation metrics of similar companies.Epigenomics is currently under evaluation in probability of bankruptcy category among related companies.
Epigenomics Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (15.90) % | |||
| Current Valuation | (9.71 M) | |||
| Shares Outstanding | 4.09 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 4.86 % | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 0.39 X | |||
| Price To Sales | 10.64 X | |||
| Revenue | 6.2 M | |||
| Gross Profit | 6.07 M | |||
| EBITDA | (1.94 M) | |||
| Net Income | (2.43 M) | |||
| Cash And Equivalents | 15.77 M | |||
| Cash Per Share | 0.96 X | |||
| Total Debt | 966 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.88 X | |||
| Book Value Per Share | 3.41 X | |||
| Cash Flow From Operations | (4.15 M) | |||
| Earnings Per Share | (0.30) X | |||
| Target Price | 8.59 | |||
| Number Of Employees | 36 | |||
| Beta | 1.08 | |||
| Market Capitalization | 6.01 M | |||
| Total Asset | 24.66 M | |||
| Retained Earnings | (62 M) | |||
| Working Capital | 5 M | |||
| Current Asset | 10 M | |||
| Current Liabilities | 5 M | |||
| Z Score | 0.8 | |||
| Net Asset | 24.66 M |
About Epigenomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Epigenomics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Epigenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Epigenomics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Epigenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epigenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epigenomics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Epigenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epigenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epigenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epigenomics AG to buy it.
The correlation of Epigenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epigenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epigenomics AG moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epigenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Epigenomics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Epigenomics Pink Sheet analysis
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |